Eli Lilly keeps its foot on dealmaking pedal, recruiting Carolyn Bertozzi’s protein degradation tech for $1.6B+

Eli Lilly is staying busy during the summer months, wheeling and dealing its way to new deals. On Wednesday, the Big Pharma sealed its latest collaboration with a biotech focused on protein degradation. Lilly is plunking down $35 million upfront and promising another $1.6 billion-plus to South San Francisco’s Lycia…

...

Click to view original post